AKTX - アカリ・セラピュ―ティクス （Akari Therapeutics Plc） アカリ・セラピュ―ティクスAKTXのチャート
AKTXの企業情報
| symbol | AKTx |
|---|---|
| 会社名 | Akari Therapeutics PLC （アカリ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Akari Therapeutics Plc formerly Celsus Therapeutics Plc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5) including paroxysmal nocturnal hemoglobinuria Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug Coversin a complement inhibitor acts on complement C5 preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases including disease states spanning hematology nephrology transplantation neurology and ophthalmology. アカリ・セラピュ―ティクスはイギリスのバイオ医薬品企業。臨床段階で、難病に対する治療薬の開発・商業化に取り組む。自己免疫の異常に起因するギラン・バレ―症候群に対するC5モノクロナ―ル抗体治療薬、また、発作性夜間ヘモグロビン尿症の治療薬の開発・商業化にも取り組む。同社パイプラインには「C5a」と「C5b-9」を含む。本社所在地は米国ニューヨーク。 |
| 本社所在地 | 75/76 Wimpole Street London 10018 GBR |
| 代表者氏名 | Ray Prudo レイプルード |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +44 20-8004-0261 |
| 設立年月日 | 38261 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 17人 |
| url | www.akaritx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aktx |
| adr_tso | 15208377 |
| EBITDA | EBITDA（百万ドル） -31.69758 |
| 終値（lastsale） | 2.05 |
| 時価総額（marketcap） | 31177172.85 |
| 時価総額 | 時価総額（百万ドル） 32.19213 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 17.12219 |
| 当期純利益 | 当期純利益（百万ドル） -31.85552 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Akari Therapeutics PLC (ADR) revenues was not reported. Net loss applicable to common stockholders decreased 27% to $9.4M. Lower net loss reflects Research and development costs decrease of 37% to $6.1M (expense) Changes in fair value of option and warr increase of 5% to $2.8M (income) Interest income increase of 71% to $132K (income). |
AKTXのテクニカル分析
AKTXのニュース
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan 2021/04/12 16:48:22 Benzinga
The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX ) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous Pemphigoid (BP), allowing clinical sites to open mid-2021, subject to the ongoing impact of COVID related restrictions. Akari has been granted orphan drug designation for nomacopan to … Full story available on Benzinga.com
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts 2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed 2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Global Guillain-Barre Syndrome Market Trends, Research, Analysis & Forecast 2028 Major Growth By Nihon Pharmaceutical Co., Ltd., CSL Behring LLC, Shire plc, Akari Therapeutics, PLC 2020/12/16 17:24:23 OpenPR
Guillain-Barre Syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress 2020/12/11 14:00:00 GlobeNewswire
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food…
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts 2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed 2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Global Guillain-Barre Syndrome Market Trends, Research, Analysis & Forecast 2028 Major Growth By Nihon Pharmaceutical Co., Ltd., CSL Behring LLC, Shire plc, Akari Therapeutics, PLC 2020/12/16 17:24:23 OpenPR
Guillain-Barre Syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress 2020/12/11 14:00:00 GlobeNewswire
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food…
Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200-Day Moving Average of $1.88 2020/10/24 15:26:44 The Olympia Report
Akari Therapeutics PLC (NASDAQ:AKTX) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares changing hands. A number of equities analysts recently commented on AKTX […]
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed 2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Global Guillain-Barre Syndrome Market Trends, Research, Analysis & Forecast 2028 Major Growth By Nihon Pharmaceutical Co., Ltd., CSL Behring LLC, Shire plc, Akari Therapeutics, PLC 2020/12/16 17:24:23 OpenPR
Guillain-Barre Syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress 2020/12/11 14:00:00 GlobeNewswire
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food…
Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200-Day Moving Average of $1.88 2020/10/24 15:26:44 The Olympia Report
Akari Therapeutics PLC (NASDAQ:AKTX) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares changing hands. A number of equities analysts recently commented on AKTX […]
Akari Therapeutics (NASDAQ:AKTX) Share Price Crosses Below Two Hundred Day Moving Average of $1.88 2020/10/23 02:20:44 US Banking News
Akari Therapeutics PLC (NASDAQ:AKTX) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares traded. AKTX has been the topic of a number of recent analyst […]